These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides. Guisado-Gil AB; Muñoz-Burgos M; Ortega-Eslava A; García-Hernández FJ; Santos-Ramos B Farm Hosp; 2020 Mar; 44(2):46-50. PubMed ID: 32452315 [TBL] [Abstract][Full Text] [Related]
7. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Delestre F; Charles P; Karras A; Pagnoux C; Néel A; Cohen P; Aumaître O; Faguer S; Gobert P; Maurier F; Samson M; Godmer P; Bonnotte B; Cottin V; Hanrotel-Saliou C; Le Gallou T; Carron PL; Desmurs-Clavel H; Direz G; Jourde-Chiche N; Lifermann F; Martin-Silva N; Pugnet G; Quéméneur T; Matignon M; Benhamou Y; Daugas E; Lazaro E; Limal N; Ducret M; Huart A; Viallard JF; Hachulla E; Perrodeau E; Puechal X; Guillevin L; Porcher R; Terrier B; Ann Rheum Dis; 2024 Jan; 83(2):233-241. PubMed ID: 37918894 [TBL] [Abstract][Full Text] [Related]
8. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA; Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA; Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823 [TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. Watanabe R; Oshima M; Nishioka N; Sada KE; Nagasaka K; Akiyama M; Ando T; Higuchi T; Inoue Y; Kida T; Mutoh T; Nakabayashi A; Onishi A; Sakai R; Waki D; Yamada Y; Yajima N; Tamura N; Kaname S; Harigai M Mod Rheumatol; 2023 Aug; 33(5):982-989. PubMed ID: 36112482 [TBL] [Abstract][Full Text] [Related]
11. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain. Macía M; Díaz-Encarnación M; Solans-Laqué R; Mallol EP; Castells AG; Escribano C; de Arellano AR Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):227-235. PubMed ID: 38126738 [TBL] [Abstract][Full Text] [Related]
12. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR; Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U; Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483 [TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Wallace ZS; Stone JH; Fu X; Merkel PA; Miloslavsky EM; Zhang Y; Choi HK; Hyle EP Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1976-1985. PubMed ID: 36645017 [TBL] [Abstract][Full Text] [Related]
15. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why? Alba MA; Flores-Suárez LF Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570 [TBL] [Abstract][Full Text] [Related]
16. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR; Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229 [TBL] [Abstract][Full Text] [Related]
17. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502 [TBL] [Abstract][Full Text] [Related]
18. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368 [TBL] [Abstract][Full Text] [Related]